Binding mode characterization of NBD series CD4-mimetic HIV-1 entry inhibitors by X-Ray structure and resistance study

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 9, 2014, Pages 5478-5491

  Curreli, Francesca ^a   Kwon, Young Do ^b   Zhang, Hongtao ^a   Yang, Yongping ^b   Scacalossi, Daniel ^a   Kwong, Peter D ^b   Debnath, Asim K ^a  

^a NEW YORK BLOOD CENTER   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; GLYCOPROTEIN GP 120; NBD 09027; NBD 10007; NBD 11008; NBD 11009; NBD 11018; NBD 556; NITROGEN; PHENYLALANINE; PIPERIDINE; SODIUM CHLORIDE; UNCLASSIFIED DRUG; N-(4-BROMOPHENYL)-N'-(2,2,6,6-TETRAMETHYLPIPERIDIN-4-YL)OXALAMIDE; N-(4-CHLOROPHENYL)-N'-(2,2,6,6-TETRAMETHYLPIPERIDIN-4-YL)OXALAMIDE; OXALIC ACID DERIVATIVE; PIPERIDINE DERIVATIVE; PROTEIN BINDING;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; BINDING SITE; CD4+ T LYMPHOCYTE; CELL FUSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG CONFORMATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROGEN BOND; HYDROPHOBICITY; IC 50; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; VIRUS MUTANT; CHEMISTRY; DRUG EFFECTS; HELA CELL LINE; HIV INFECTIONS; METABOLISM; PHYSIOLOGY; PROCEDURES; TUMOR CELL LINE; X RAY CRYSTALLOGRAPHY;

ANTI-HIV AGENTS; ANTIGENS, CD4; CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; HELA CELLS; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; OXALATES; PIPERIDINES; PROTEIN BINDING;

EID: 84906074757     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03339-14     Document Type: Article

References (65)

1. Cooley LA, Lewin SR. 2003. HIV-1 cell entry and advances in viral entry inhibitor therapy. J. Clin. Virol. 26:121-132. http://dx.doi.org/10.1016/S1386- 6532(02)00111-7. (Pubitemid 36206597)
2. Jiang S, Debnath AK. 2000. Development of HIV entry inhibitors targeted to the coiled coil regions of gp41. Biochem. Biophys. Res. Commun. 269:641-646. http://dx.doi.org/10.1006/bbrc.1999.1972. (Pubitemid 30440354)
3. Singh IP, Chauthe SK. 2011. Small molecule HIV entry inhibitors. Part II. Attachment and fusion inhibitors: 2004-2010. Expert. Opin. Ther. Pat. 21:399-416.
4. Duffalo ML, James CW. 2003. Enfuvirtide: a novel agent for the treatment of HIV-1 infection. Ann. Pharmacother. 37:1448-1456. http://dx.doi.org/10.1345/ aph.1D143. (Pubitemid 37205504)
5. Lieberman-Blum SS, Fung HB, Bandres JC. 2008. Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection. Clin. Ther. 30:1228-1250. http://dx.doi.org/10.1016/S0149-2918(08)80048-3.
6. MacArthur RD, Novak RM. 2008. Maraviroc: the first of a new class of antiretroviral agents. Clin. Infect. Dis. 47:236-241. http://dx.doi.org/10.1086/ 589289. (Pubitemid 351920626)
7. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. 1998. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393:648-659. http://dx.doi.org/10.1038/31405. (Pubitemid 28289647)
8. Smith DH, Byrn RA, Marsters SA, Gregory T, Groopman JE, Capon DJ. 1987. Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen. Science 238:1704-1707. http://dx.doi.org/10.1126/science.3500514. (Pubitemid 18046271)
9. Hussey RE, Richardson NE, Kowalski M, Brown NR, Chang HC, Siliciano RF, Dorfman T, Walker B, Sodroski J, Reinherz EL. 1988. A soluble CD4 protein selectively inhibits HIV replication and syncytium formation. Nature 331:78-81. http://dx.doi.org/10.1038/331078a0. (Pubitemid 18053421)
10. Daar ES, Li XL, Moudgil T, Ho DD. 1990. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc. Natl. Acad. Sci. U. S. A. 87:6574-6578. http://dx.doi.org/10.1073/pnas.87.17.6574.
11. Martin L, Stricher F, Misse D, Sironi F, Pugniere M, Barthe P, Prado-Gotor R, Freulon I, Magne X, Roumestand C, Menez A, Lusso P, Veas F, Vita C. 2003. Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes. Nat. Biotechnol. 21:71-76. http://dx.doi.org/ 10.1038/nbt768. (Pubitemid 36055830)
12. Lin PF, Blair W, Wang T, Spicer T, Guo Q, Zhou N, Gong YF, Wang HG, Rose R, Yamanaka G, Robinson B, Li CB, Fridell R, Deminie C, Demers G, Yang Z, Zadjura L, Meanwell N, Colonno R. 2003. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc. Natl. Acad. Sci. U. S. A. 100:11013-11018. http://dx.doi.org/10.1073/pnas.1832214100. (Pubitemid 37140144)
13. Madani N, Perdigoto AL, Srinivasan K, Cox JM, Chruma JJ, LaLonde J, Head M, Smith AB, Sodroski JG, III. 2004. Localized changes in the gp120 envelope glycoprotein confer resistance to human immunodeficiency virus entry inhibitors BMS-806 and #155. J. Virol. 78:3742-3752. http://dx.doi.org/10.1128/JVI.78.7. 3742-3752.2004. (Pubitemid 38578378)
14. Zhao Q, Ma L, Jiang S, Lu H, Liu S, He Y, Strick N, Neamati N, Debnath AK. 2005. Identification of N-phenyl-N′-(2,2,6,6-tetramethyl-piperidin-4- yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. Virology 339:213-225. http://dx.doi.org/10.1016/j.virol.2005.06. 008. (Pubitemid 41169789)
15. Hashimoto C, Narumi T, Otsuki H, Hirota Y, Arai H, Yoshimura K, Harada S, Ohashi N, Nomura W, Miura T, Igarashi T, Matsushita S, Tamamura H. 2013. A CD4 mimic as an HIV entry inhibitor: pharmacokinetics. Bioorg. Med. Chem. 21:7884-7889. http://dx.doi.org/10.1016/j.bmc.2013.10.005.
16. Narumi T, Arai H, Yoshimura K, Harada S, Hirota Y, Ohashi N, Hashimoto C, Nomura W, Matsushita S, Tamamura H. 2013. CD4 mimics as HIV entry inhibitors: lead optimization studies of the aromatic substituents. Bioorg. Med. Chem. 21:2518-2526. http://dx.doi.org/10.1016/j.bmc.2013.02.041.
17. Narumi T, Ochiai C, Yoshimura K, Harada S, Tanaka T, Nomura W, Arai H, Ozaki T, Ohashi N, Matsushita S, Tamamura H. 2010. CD4 mimics targeting the HIV entry mechanism and their hybrid molecules with a CXCR4 antagonist. Bioorg. Med. Chem. Lett. 20:5853-5858. http://dx.doi.org/10.1016/j.bmcl.2010.07.106.
18. Narumi T, Arai H, Yoshimura K, Harada S, Nomura W, Matsushita S, Tamamura H. 2011. Small molecular CD4 mimics as HIV entry inhibitors. Bioorg. Med. Chem. 19:6735-6742. http://dx.doi.org/10.1016/j.bmc.2011.09.045.
19. Haim H, Si Z, Madani N, Wang L, Courter JR, Princiotto A, Kassa A, DeGrace M, Gee-Estrada K, Mefford M, Gabuzda D, Smith AB, Sodroski J, III. 2009. Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state. PLoS Pathog. 5:e1000360. http://dx.doi.org/10. 1371/journal.ppat.1000360.
20. Kwon YD, Lalonde JM, Yang Y, Elban MA, Sugawara A, Courter JR, Jones DM, Smith AB, Debnath IIIAK, Kwong PD. 2014. Crystal structures of HIV-1 gp120 envelope glycoprotein in complex with NBD analogues that target the CD4-binding site. PLoS One 9:e85940. http://dx.doi.org/10.1371/journal.pone.0085940.
21. LaLonde JM, Elban MA, Courter JR, Sugawara A, Soeta T, Madani N, Princiotto AM, Kwon YD, Kwong PD, Schon A, Freire E, Sodroski J, Smith AB, III. 2011. Design, synthesis and biological evaluation of small molecule inhibitors of CD4-gp120 binding based on virtual screening. Bioorg. Med. Chem. 19:91-101. http://dx.doi.org/10.1016/j.bmc.2010.11.049.
22. LaLonde JM, Kwon YD, Jones DM, Sun AW, Courter JR, Soeta T, Kobayashi T, Princiotto AM, Wu X, Schon A, Freire E, Kwong PD, Mascola JR, Sodroski J, Madani N, Smith AB, III. 2012. Structure-based design, synthesis, and characterization of dual hotspot small-molecule HIV-1 entry inhibitors. J. Med. Chem. 55:4382-4396. http://dx.doi.org/10.1021/jm300265j.
23. Lalonde JM, Le-Khac M, Jones DM, Courter JR, Park J, Schon A, Princiotto AM, Wu X, Mascola JR, Freire E, Sodroski J, Madani N, Hendrickson WA, Smith AB, III. 2013. Structure-based design and synthesis of an HIV-1 entry inhibitor exploiting X-ray and thermodynamic characterization. ACS Med. Chem. Lett. 4:338-343. http://dx.doi.org/10.1021/ml300407y.
24. Madani N, Schon A, Princiotto AM, Lalonde JM, Courter JR, Soeta T, Ng D, Wang L, Brower ET, Xiang SH, Kwon YD, Huang CC, Wyatt R, Kwong PD, Freire E, Smith AB, Sodroski J, III. 2008. Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120. Structure 16:1689-1701. http://dx.doi.org/10.1016/j.str.2008.09.005.
25. Schon A, Madani N, Klein JC, Hubicki A, Ng D, Yang X, Smith AB, Sodroski J, III, Freire E. 2006. Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120. Biochemistry 45:10973-10980. http://dx.doi.org/10.1021/ bi061193r. (Pubitemid 44360167)
26. Yamada Y, Ochiai C, Yoshimura K, Tanaka T, Ohashi N, Narumi T, Nomura W, Harada S, Matsushita S, Tamamura H. 2010. CD4 mimics targeting the mechanism of HIV entry. Bioorg. Med. Chem. Lett. 20:354-358. http://dx.doi.org/10.1016/j. bmcl.2009.10.098.
27. Yoshimura K, Harada S, Shibata J, Hatada M, Yamada Y, Ochiai C, Tamamura H, Matsushita S. 2010. Enhanced exposure of human immunodeficiency virus type 1 primary isolate neutralization epitopes through binding of CD4 mimetic compounds. J. Virol. 84:7558-7568. http://dx.doi.org/10.1128/JVI.00227-10.
28. Kwon YD, Finzi A, Wu X, Dogo-Isonagie C, Lee LK, Moore LR, Schmidt SD, Stuckey J, Yang Y, Zhou T, Zhu J, Vicic DA, Debnath AK, Shapiro L, Bewley CA, Mascola JR, Sodroski JG, Kwong PD. 2012. Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops. Proc. Natl. Acad. Sci. U. S. A. 109:5663-5668. http://dx.doi.org/10.1073/pnas.1112391109.
29. Curreli F, Choudhury S, Pyatkin I, Zagorodnikov VP, Bulay AK, Altieri A, Kwon YD, Kwong PD, Debnath AK. 2012. Design, synthesis and antiviral activity of entry inhibitors that target the CD4-binding site of HIV-1. J. Med. Chem. 55:4764-4775. http://dx.doi.org/10.1021/jm3002247.
30. Weiss A, Wiskocil RL, Stobo JD. 1984. The role of T3 surface molecules in the activation of human T cells: a two-stimulus requirement for IL 2 production reflects events occurring at a pre-translational level. J. Immunol. 133:123-128. (Pubitemid 14076697)
31. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D. 1998. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J. Virol. 72:2855-2864. (Pubitemid 28175522)
32. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu X, Shaw GM, Kappes JC. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46:1896-1905. http://dx.doi.org/10.1128/AAC.46.6.1896-1905.2002. (Pubitemid 34535213)
33. Kolchinsky P, Mirzabekov T, Farzan M, Kiprilov E, Cayabyab M, Mooney LJ, Choe H, Sodroski J. 1999. Adaptation of a CCR5-using, primary human immunodeficiency virus type 1 isolate for CD4-independent replication. J. Virol. 73:8120-8126. (Pubitemid 29441672)
34. Bjorndal A, Deng H, Jansson M, Fiore JR, Colognesi C, Karlsson A, Albert J, Scarlatti G, Littman DR, Fenyo EM. 1997. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J. Virol. 71:7478-7487. (Pubitemid 27391688)
35. Page KA, Landau NR, Littman DR. 1990. Construction and use of a human immunodeficiency virus vector for analysis of virus infectivity. J. Virol. 64:5270-5276. (Pubitemid 20364514)
36. Blish CA, Jalalian-Lechak Z, Rainwater S, Nguyen MA, Dogan OC, Overbaugh J. 2009. Cross-subtype neutralization sensitivity despite monoclonal antibody resistance among early subtype A, C, and D envelope variants of human immunodeficiency virus type 1. J. Virol. 83:7783-7788. http://dx.doi.org/10. 1128/JVI.00673-09.
37. Long EM, Rainwater SM, Lavreys L, Mandaliya K, Overbaugh J. 2002. HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus. AIDS Res. Hum. Retroviruses 18:567-576. http://dx.doi.org/10.1089/088922202753747914. (Pubitemid 34579536)
38. Kulkarni SS, Lapedes A, Tang H, Gnanakaran S, Daniels MG, Zhang M, Bhattacharya T, Li M, Polonis VR, McCutchan FE, Morris L, Ellenberger D, Butera ST, Bollinger RC, Korber BT, Paranjape RS, Montefiori DC. 2009. Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtypeCHIV-1EnvclonesfromIndia. Virology 385:505-520. http://dx.doi.org/10. 1016/j.virol.2008.12.032.
39. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, Voss G, Goepfert P, Gilbert P, Greene KM, Bilska M, Kothe DL, Salazar-Gonzalez JF, Wei X, Decker JM, Hahn BH, Montefiori DC. 2005. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79:10108-10125. http://dx.doi.org/10.1128/JVI.79.16.10108-10125.2005. (Pubitemid 41098552)
40. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, Komarova NL, Nowak MA, Hahn BH, Kwong PD, Shaw GM. 2003. Antibody neutralization and escape by HIV-1. Nature 422:307-312. http://dx.doi.org/10.1038/nature01470. (Pubitemid 36378357)
41. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, Sun C, Grayson T, Wang S, Li H, Wei X, Jiang C, Kirchherr JL, Gao F, Anderson JA, Ping LH, Swanstrom R, Tomaras GD, Blattner WA, Goepfert PA, Kilby JM, Saag MS, Delwart EL, Busch MP, Cohen MS, Montefiori DC, Haynes BF, Gaschen B, Athreya GS, Lee HY, Wood N, Seoighe C, Perelson AS, Bhattacharya T, Korber BT, Hahn BH, Shaw GM. 2008. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci. U. S. A. 105:7552-7557. http://dx.doi.org/10.1073/pnas.0802203105. (Pubitemid 351830056)
42. Derdeyn CA, Decker JM, Bibollet-Ruche F, Mokili JL, Muldoon M, Denham SA, Heil ML, Kasolo F, Musonda R, Hahn BH, Shaw GM, Korber BT, Allen S, Hunter E. 2004. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 303:2019-2022. http://dx.doi.org/10.1126/science.1093137. (Pubitemid 38393277)
43. Li M, Salazar-Gonzalez JF, Derdeyn CA, Morris L, Williamson C, Robinson JE, Decker JM, Li Y, Salazar MG, Polonis VR, Mlisana K, Karim SA, Hong K, Greene KM, Bilska M, Zhou J, Allen S, Chomba E, Mulenga J, Vwalika C, Gao F, Zhang M, Korber BT, Hunter E, Hahn BH, Montefiori DC. 2006. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J. Virol. 80: 11776 -11790. http://dx.doi.org/10.1128/JVI.01730-06.
44. Williamson C, Morris L, Maughan MF, Ping LH, Dryga SA, Thomas R, Reap EA, Cilliers T, van Harmelen J, Pascual A, Ramjee G, Gray G, Johnston R, Karim SA, Swanstrom R. 2003. Characterization and selection of HIV-1 subtype Cisolates for use in vaccine development. AIDS Res. Hum. Retroviruses 19:133-144. http://dx.doi.org/10.1089/088922203762688649. (Pubitemid 36308051)
45. Connor RI, Chen BK, Choe S, Landau NR. 1995. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 206:935-944. http://dx.doi.org/10.1006/viro.1995.1016.
46. cdc2 activity. J. Virol. 69:6705-6711.
47. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A, Martin MA. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284-291. (Pubitemid 16013975)
48. Si Z, Phan N, Kiprilov E, Sodroski J. 2003. Effects of HIV type 1 envelope glycoprotein proteolytic processing on antigenicity. AIDS Res. Hum. Retroviruses 19:217-226. http://dx.doi.org/10.1089/088922203763315722. (Pubitemid 36359887)
49. Jiang S, Radigan L, Zhang L. 2000. A convenient cell fusion assay for rapid screening for HIV entry inhibitors. Proc. SPIE 3926:212-219. http://dx.doi.org/10.1117/12.380514. (Pubitemid 30586008)
50. Si Z, Madani N, Cox JM, Chruma JJ, Klein JC, Schon A, Phan N, Wang L, Biorn AC, Cocklin S, Chaiken I, Freire E, Smith AB, Sodroski JG, III. 2004. Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins. Proc. Natl. Acad. Sci. U. S. A. 101:5036-5041. http://dx.doi.org/10.1073/pnas.0307953101. (Pubitemid 38469198)
51. Jiang S, Lu H, Liu S, Zhao Q, He Y, Debnath AK. 2004. N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion. Antimicrob. Agents Chemother. 48:4349-4359. http://dx.doi.org/10. 1128/AAC.48.11.4349-4359.2004. (Pubitemid 39434898)
52. Otwinowski Z, Minor W. 1997. Macromolecular crystallography, part A. Methods Enzymol. 276:307-326.
53. Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW, McCoy AJ, Moriarty NW, Oeffner R, Read RJ, Richardson DC, Richardson JS, Terwilliger TC, Zwart PH. 2010. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr.DBiol. Crystallogr. 66:213-221. http://dx.doi.org/10.1107/ S0907444909052925.
54. Emsley P, Cowtan K. 2004. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60:2126-2132. http://dx.doi.org/10.1107/S0907444904019158. (Pubitemid 41742764)
55. Wallace AC, Laskowski RA, Thornton JM. 1995. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng. 8:127-134. http://dx.doi.org/10.1093/protein/8.2.127.
56. Mascola JR, D'Souza P, Gilbert P, Hahn BH, Haigwood NL, Morris L, Petropoulos CJ, Polonis VR, Sarzotti M, Montefiori DC. 2005. Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J. Virol. 79:10103-10107. http://dx.doi.org/10.1128/JVI.79.16.10103-10107.2005. (Pubitemid 41098551)
57. Bunnik EM, van Gils MJ, Lobbrecht MS, Pisas L, Nanlohy NM, van Baarle D, van Nuenen AC, Hessell AJ, Schuitemaker H. 2010. Emergence of monoclonal antibody b12-resistant human immunodeficiency virus type 1 variants during natural infection in the absence of humoral or cellular immune pressure. J. Gen. Virol. 91:1354-1364. http://dx.doi.org/10.1099/vir.0.017319-0.
58. Schader SM, Colby-Germinario SP, Quashie PK, Oliveira M, Ibanescu RI, Moisi D, Mesplede T, Wainberg MA. 2012. HIV gp120 H375 is unique to HIV-1 subtypeCRF01-AEand confers strong resistance to the entry inhibitor BMS-599793, a candidate microbicide drug. Antimicrob. Agents Chemother. 56:4257-4267. http://dx.doi.org/10.1128/AAC.00639-12.
59. Zerhouni B, Nelson JA, Saha K. 2004. Isolation of CD4-independent primary human immunodeficiency virus type 1 isolates that are syncytium inducing and acutely cytopathic for CD8+ lymphocytes. J. Virol. 78:1243-1255. http://dx.doi.org/10.1128/JVI.78.3.1243-1255.2004. (Pubitemid 38095834)
60. Zwick MB, Kelleher R, Jensen R, Labrijn AF, Wang M, Quinnan GV, Jr, Parren PW, Burton DR. 2003. A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12. J. Virol. 77:6965-6978. http://dx.doi.org/10.1128/JVI.77.12.6965-6978.2003. (Pubitemid 36666889)
61. Stamatatos L, Cheng-Mayer C. 1995. Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerization and differential V3 loop epitope exposure of isolates displaying distinct tropism upon virion-soluble receptor binding. J. Virol. 69:6191-6198.
62. Wyatt R, Moore J, Accola M, Desjardin E, Robinson J, Sodroski J. 1995. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J. Virol. 69:5723-5733.
63. Wang T, Zhang Z, Wallace OB, Deshpande M, Fang H, Yang Z, Zadjura LM, Tweedie DL, Huang S, Zhao F, Ranadive S, Robinson BS, Gong YF, Ricarrdi K, Spicer TP, Deminie C, Rose R, Wang HG, Blair WS, Shi PY, Lin PF, Colonno RJ, Meanwell NA. 2003. Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b] pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions. J. Med. Chem. 46:4236-4239. http://dx.doi.org/10.1021/jm034082o. (Pubitemid 37153004)
64. Madani N, Princiotto AM, Schon A, Lalonde J, Feng Y, Freire E, Park J, Courter JR, Jones DM, Robinson J, Liao HX, Moody MA, Permar S, Haynes B, Smith AB, Wyatt R, Sodroski J, III. 2014. CD4-mimetic small molecules sensitize human immunodeficiency virus (HIV-1) to vaccine-elicited antibodies. J. Virol. 88:6542-6555. http://dx.doi.org/10.1128/JVI.00540-14.
65. Courter JR, Madani N, Sodroski J, Schon A, Freire E, Kwong PD, Hendrickson WA, Chaiken IM, Lalonde JM, Smith AB, III. 2014. Structure-based design, synthesis and validation of CD4-mimetic small molecule inhibitors of HIV-1 entry: conversion of a viral entry agonist to an antagonist. ACC Chem. Res. 47:1228-1237. http://dx.doi.org/10.1021/ar4002735.